Arecor on Investor Meet Company Platform
Arecor Therapeutics plc
("Arecor" or the "Group")
Arecor to present on Investor Meet Company Platform
Cambridge, UK, 21 April 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that Sarah Howell, Chief Executive Officer and Susan Lowther, Chief Financial Officer will be providing a live presentation relating to the Group's recently announced results for the year ended 31 December 2022 via the Investor Meet Company platform, on Wednesday 26 April 2023 at 14.00pm BST.
The presentation is open to all existing and potential shareholders and will be followed by a Q&A session. Questions can be submitted ahead of the event through the Investor Meet Company dashboard until 9am BST on Tuesday 25 April, or at any time during the live presentation.
To sign up to Investor Meet Company for free and to register for Arecor's presentation, please visit:
https://www.investormeetcompany.com/arecor-therapeutics-plc/register-investor.
Investors who already follow Arecor on the Investor Meet Company platform will automatically be invited to the event.
-ENDS-
For more information, please contact:
|
Arecor Therapeutics plc |
|
|
Dr Sarah Howell, Chief Executive Officer |
Tel: +44 (0) 1223 426060 Email: info@arecor.com |
|
|
|
|
Susan Lowther, Chief Financial Officer |
Tel: +44 (0) 1223 426060 Email: info@arecor.com |
|
|
|
|
Mo Noonan, Communications |
Tel: +44 (0) 7876 444977 Email: mo.noonan@arecor.com |
|
|
|
|
Panmure Gordon (UK) Limited (NOMAD and Broker) |
|
|
Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) |
Tel: +44 (0) 20 7886 2500
|
|
|
|
|
Consilium Strategic Communications |
|
|
Chris Gardner, David Daley, Lindsey Neville |
Tel: +44 (0) 20 3709 5700 Email: arecor@consilium-comms.com |
|
|
|
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com
-
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago IntegraFin Holding
- 1 day ago Spirent Communications
- 1 day ago CRH (CDI)
- 1 day ago Bezant Resources
- 1 day ago EJF Investments Ltd NPV